Patents by Inventor Ponnal Nambi

Ponnal Nambi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinolines and pharmaceutical compositions thereof
    Patent number: 7576215
    Abstract: This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: August 18, 2009
    Assignee: Wyeth
    Inventors: Michael D. Collini, Robert R. Singhaus, Jr., Baihua Hu, James W. Jetter, Robert L. Morris, David H. Kaufman, Christopher P. Miller, John W. Ullrich, Rayomand J. Unwalla, Jay E. Wrobel, Elaine Quinet, Ponnal Nambi, Ronald C. Bernotas, Merle Elloso
  • Human LXR? variants
    Patent number: 7341850
    Abstract: This invention provides novel human LXR? variant polypeptides and nucleic acids encoding such polypeptides. This invention also provides the therapeutic, diagnostic, and research utilities as well as the production of such polynucleotides and polypeptides. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: March 11, 2008
    Assignee: Wyeth
    Inventors: Qiang-Yuan Liu, Ponnal Nambi
  • Novel human LXRalpha variants
    Publication number: 20070218550
    Abstract: This invention provides novel human LXR? variant polypeptides and nucleic acids encoding such polypeptides. This invention also provides the therapeutic, diagnostic, and research utilities as well as the production of such polynucleotides and polypeptides. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: December 13, 2006
    Publication date: September 20, 2007
    Applicant: Wyeth
    Inventors: Qiang-Yuan Liu, Ponnal Nambi
  • 5-Lipoxygenase modulators
    Publication number: 20070093524
    Abstract: The present invention provides the use of Liver X Receptor (LXR) modulators that have been identified to downregulate 5-lipoxygenase gene expression in order to treat various diseases and disorders that involve the function of the 5-LO protein in intracellular signaling (or other cellular processes) or the function of protein products downstream of 5-LO in intracellular signaling (i.e., leukotrienes).
    Type: Application
    Filed: October 6, 2006
    Publication date: April 26, 2007
    Applicant: Wyeth
    Inventors: Ponnal Nambi, Liang Chen, Elaine Quinet, Jay Wrobel
  • Quinolines useful in treating cardiovascular disease
    Publication number: 20050131014
    Abstract: This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.
    Type: Application
    Filed: December 10, 2004
    Publication date: June 16, 2005
    Applicant: Wyeth
    Inventors: Michael Collini, Robert Singhaus, Baihua Hu, James Jetter, Robert Morris, David Kaufman, Christopher Miller, John Ullrich, Rayomand Unwalla, Jay Wrobel, Elaine Quinet, Ponnal Nambi, Ronald Bernotas, Merle Elloso
  • Novel human LXRalpha variants
    Publication number: 20050095677
    Abstract: This invention provides novel human LXR? variant polypeptides and nucleic acids encoding such polypeptides. This invention also provides the therapeutic, diagnostic, and research utilities as well as the production of such polynucleotides and polypeptides. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).
    Type: Application
    Filed: August 18, 2004
    Publication date: May 5, 2005
    Applicant: Wyeth
    Inventors: Qiang-Yuan Liu, Ponnal Nambi
  • HAS2 splicing variant HOEFC11: a target in chronic renal failure, inflammatory diseases and myocardial ischemia
    Patent number: 6350446
    Abstract: HOEFC11 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HOEFC11 polypeptides and polynucleotides in the design of protocols for the treatment of chronic renal failure, inflammatory diseases, myocardial ischemia, cancer, rheumatoid arthritis, cirrhotic liver disease, among others, and diagnostic assays for such conditions.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: February 26, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Yuan Zhu, Ponnal Nambi, Mark A Pullen
  • HAS2 splicing variant HOEFC11: a target in chronic renal failure, inflammatory diseases and myocardial ischemia
    Patent number: 5994100
    Abstract: HOEFC11 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HOEFC11 polypeptides and polynucleotides in the design of protocols for the treatment of chronic renal failure, inflammatory diseases, myocardial ischemia, cancer, rheumatoid arthritis, cirrhotic liver disease, among others, and diagnostic assays for such conditions.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: November 30, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Yuan Zhu, Ponnal Nambi, Mark A Pullen
  • Protein Kinase C inhibitor
    Patent number: 5616577
    Abstract: The present invention relates to treatment of conditions wherein protein Kinase C inhibition is indicated.
    Type: Grant
    Filed: July 29, 1996
    Date of Patent: April 1, 1997
    Assignee: SmithKline Beecham Corporation
    Inventors: Ponnal Nambi, Ashok D. Patil
  • Medicament
    Patent number: 5565448
    Abstract: The present invention relates to the treatment and prevention of conditions wherein protein Kinase C inhibition is indicated.
    Type: Grant
    Filed: August 25, 1994
    Date of Patent: October 15, 1996
    Assignee: SmithKline Beecham Corporation
    Inventors: Ponnal Nambi, Ashok D. Patil